title: An evaluation of the usefulness of mycophenolate mofetil in pemphigus.
abstract: BACKGROUND
  Pemphigus is a group of autoimmune blistering diseases of the skin and/or mucous membranes requiring management with immunosuppressive therapy. The optimal therapeutic regimen would rapidly induce remission and maintain effectiveness with minimal adverse effects in the long term.
  
  
  OBJECTIVE
  The present study describes our experience of the addition of mycophenolate mofetil (MMF) to prednisolone in the management of severe, refractory pemphigus.
  
  
  METHODS
  Patients with active, refractory pemphigus were treated with MMF. Our series included 12 cases of pemphigus vulgaris, four cases of pemphigus foliaceous and one case of paraneoplastic pemphigus. All patients were monitored to assess disease control and mycophenolate toxicity.
  
  
  RESULTS
  Of the 17 cases, MMF has been of benefit to 12. MMF was well tolerated and there were no treatment withdrawals because of safety concerns.
  
  
  CONCLUSIONS
  We found that MMF permitted a reduction in prednisolone dosage without disease relapse.
authors.affiliation: Department of Immunofluorescence, St John's Institute of Dermatology, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, U.K. amipowell@doctors.org.uk
authors.forename: A M
authors.initials: AM
authors.lastname: Powell
authors.forename: S
authors.initials: S
authors.lastname: Albert
authors.forename: S
authors.initials: S
authors.lastname: Al Fares
authors.forename: K E
authors.initials: KE
authors.lastname: Harman
authors.forename: J
authors.initials: J
authors.lastname: Setterfield
authors.forename: B
authors.initials: B
authors.lastname: Bhogal
authors.forename: M M
authors.initials: MM
authors.lastname: Black
mesh_terms: D000328:Adult; D000368:Aged; D001327:Autoimmune Diseases / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D010257:Paraneoplastic Syndromes / Q000188:drug therapy; D010392:Pemphigus / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011239:Prednisolone; D009173:Mycophenolic Acid